American Association for Long-Term Care Insurance

Researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal explain that MS is an autoimmune disease in which the body’s own immune response attacks the central nervous system, almost as if the body had become allergic to itself, leading to progressive physical and cognitive disability.

The new treatment, appropriately named GIFT15, puts MS into remission by suppressing the immune response. This means it might also be effective against other autoimmune disorders like Crohn’s disease, lupus and arthritis, the researchers said, and could theoretically also control immune responses in organ transplant patients.

Unlike earlier immune-suppressing therapies which rely on chemical pharmaceuticals, this approach is a personalized form of cellular therapy which utilizes the body’s own cells to suppress immunity in a much more targeted way.

GIFT15 was discovered by a team led by Dr. Jacques Galipeau of the JGH Lady Davis Institute and McGill’s Faculty of Medicine.    GIFT15 is a new protein hormone composed of two distinct proteins, and when they’re stuck together they lead to a completely unexpected biological effect.

This effect, explained Galipeau, converts B-cells — a common form of white blood cell normally involved in immune response — into powerful immune-suppressive cells. Unlike their better-known cousins, T-cells, naturally-occurring immune-suppressing B-cells are almost unknown in nature and the notion of using them to control immunity is very new.

Reported by the American Association for Long-Term Care Insuramnce.  Read our free guide on reducing the cost of long-term care insurance.

Tags: American Association for Long-Term Care Insurance, health news, medical research, Medicare, multiple sclerosis, women

This entry was posted on Monday, December 21st, 2009. Trackback from your own site.